New drug cocktail aims to outsmart ALK lung cancer

NCT ID NCT06007937

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the cancer from growing. About 56 participants will be enrolled at Memorial Sloan Kettering Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib (a targeted therapy pill) and ramucirumab (an intravenous antibody that blocks blood vessel growth)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with advanced ALK-positive lung cancer, potentially slowing tumor growth longer than current therapies.
What could go wrong: This is an early-phase trial with only 56 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to improve outcomes compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis non-small cell lung carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER RECURRENT

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)

Rockville Centre, New York, 11570, United States
Memorial Sloan Kettering West Harrison (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.